Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research
Adoptive cell therapy (ACT) is a kind of immunotherapy in which T cells are genetically modified to express a chimeric antigen receptor (CAR) or T cell receptor (TCR), and ACT has made a great difference in treating multiple types of tumors. ACT is not perfect, and it can be followed by severe side...
Main Authors: | Zhidong Wang, Yu J. Cao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00176/full |
Similar Items
-
Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy
by: Daniel J. Verdon, et al.
Published: (2021-08-01) -
T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
by: Else M. Inderberg, et al.
Published: (2017-04-01) -
Novel strategies for immuno-oncology breakthroughs with cell therapy
by: Hongtao Liu, et al.
Published: (2021-07-01) -
Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies
by: Florian Kast, et al.
Published: (2021-01-01) -
Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies
by: Vanessa M. Tubb, et al.
Published: (2018-07-01)